HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC)

Seligmann, JF, Elliott, F, Jacobs, B et al. (10 more authors) (2015) HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC). In: Journal of Clinical Oncology. 2015 ASCO Annual Meeting, 29 May - 02 Jun 2015, Chicago, IL. American Society of Clinical Oncology .

Metadata

Authors/Creators:
  • Seligmann, JF
  • Elliott, F
  • Jacobs, B
  • Hatch, AJ
  • Sibley, A
  • Richman, S
  • Jiang, C
  • Barrett, J
  • Owzar, K
  • Quirke, P
  • Hurwitz, H
  • Seymour, MT
  • Nixon, AB
Dates:
  • Published: 20 May 2015
  • Accepted: 27 March 2015
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 05 Feb 2016 09:57
Last Modified: 05 Feb 2016 09:57
Published Version: http://meeting.ascopubs.org/cgi/content/abstract/3...
Status: Published
Publisher: American Society of Clinical Oncology
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export